Iwahashi N, Ikezaki M, Komohara Y, Fujiwara Y, Noguchi T, Nishioka K, et al. Cytoplasmic p53 aggregates accumulated in p53-mutated cancer correlate with poor prognosis. PNAS Nexus. 2022;1:pgac128 pubmed publisher

Gao X, Zheng X, Zhang Y, Dong L, Sun L, Zhao N, et al. Deficient or R273H and R248W Mutations of p53 Promote Chemoresistance to 5-FU via TCF21/CD44 Axis-Mediated Enhanced Stemness in Colorectal Carcinoma. Front Cell Dev Biol. 2021;9:788331 pubmed publisher

Palanikumar L, Karpauskaite L, Al Sayegh M, Chehade I, Alam M, Hassan S, et al. Protein mimetic amyloid inhibitor potently abrogates cancer-associated mutant p53 aggregation and restores tumor suppressor function. Nat Commun. 2021;12:3962 pubmed publisher

Hanaford A, Alt J, Rais R, Wang S, Kaur H, Thorek D, et al. Orally bioavailable glutamine antagonist prodrug JHU-083 penetrates mouse brain and suppresses the growth of MYC-driven medulloblastoma. Transl Oncol. 2019;12:1314-1322 pubmed publisher

Aggarwal M, Saxena R, Asif N, Sinclair E, Tan J, Cruz I, et al. p53 mutant-type in human prostate cancer cells determines the sensitivity to phenethyl isothiocyanate induced growth inhibition. J Exp Clin Cancer Res. 2019;38:307 pubmed publisher

Yang Hartwich Y, Tedja R, Roberts C, Goodner Bingham J, Cardenas C, Gurea M, et al. p53-Pirh2 Complex Promotes Twist1 Degradation and Inhibits EMT. Mol Cancer Res. 2019;17:153-164 pubmed publisher

Schulz Heddergott R, Stark N, Edmunds S, Li J, Conradi L, Bohnenberger H, et al. Therapeutic Ablation of Gain-of-Function Mutant p53 in Colorectal Cancer Inhibits Stat3-Mediated Tumor Growth and Invasion. Cancer Cell. 2018;34:298-314.e7 pubmed publisher

Mircetic J, Dietrich A, Paszkowski Rogacz M, Krause M, Buchholz F. Development of a genetic sensor that eliminates p53 deficient cells. Nat Commun. 2017;8:1463 pubmed publisher

Gopalakrishnapillai A, Kolb E, McCahan S, Barwe S. Epigenetic drug combination induces remission in mouse xenograft models of pediatric acute myeloid leukemia. Leuk Res. 2017;58:91-97 pubmed publisher

Karthikeyan S, Lantvit D, Chae D, Burdette J. Cadherin-6 type 2, K-cadherin (CDH6) is regulated by mutant p53 in the fallopian tube but is not expressed in the ovarian surface. Oncotarget. 2016;7:69871-69882 pubmed publisher

Hanaford A, Archer T, Price A, Kahlert U, Maciaczyk J, Nikkhah G, et al. DiSCoVERing Innovative Therapies for Rare Tumors: Combining Genetically Accurate Disease Models with In Silico Analysis to Identify Novel Therapeutic Targets. Clin Cancer Res. 2016;22:3903-14 pubmed publisher

Labrie M, Vladoiu M, Grosset A, Gaboury L, St Pierre Y. Expression and functions of galectin-7 in ovarian cancer. Oncotarget. 2014;5:7705-21 pubmed

Campion C, Labrie M, Lavoie G, St Pierre Y. Expression of galectin-7 is induced in breast cancer cells by mutant p53. PLoS ONE. 2013;8:e72468 pubmed publisher

Mao X, Hütt Cabezas M, Orr B, Weingart M, Taylor I, Rajan A, et al. LIN28A facilitates the transformation of human neural stem cells and promotes glioblastoma tumorigenesis through a pro-invasive genetic program. Oncotarget. 2013;4:1050-64 pubmed

Saleh A, Savage J, Cao L, Soule B, Ly D, DeGraff W, et al. Cellular stress induced alterations in microRNA let-7a and let-7b expression are dependent on p53. PLoS ONE. 2011;6:e24429 pubmed publisher

Baker S, Markowitz S, Fearon E, Willson J, Vogelstein B. Suppression of human colorectal carcinoma cell growth by wild-type p53. Science. 1990;249:912-5 pubmed